Be Biopharma - Advancing our science with bold humanity
WEB3 days ago · Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Life at Be Bio - Be Biopharma
WEBHere at Be Bio we are on an important journey to unleash the power of cell therapies beyond cell-cell contact-dependent killing (e.g., CAR-T cells); we are developing a proprietary class of engineered B cell medicines.
Be Bio Closes $130 Million Financing to Pioneer ... - Be Biopharma
WEBCAMBRIDGE, Mass. April 14, 2022 – Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced the closing of a $130 million financing, bringing the total investment in the Company to over $180 million.
News Releases - Be Biopharma
WEBJun 4, 2024 · Read More about Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained …
Our Science - Be Biopharma
WEBJul 2, 2024 · Unleashing nature’s manufacturing powerhouse. B cells are nature’s exquisitely tuned medicine factories, manufacturing proteins to fight disease and maintain health.
Contact Us - Be Biopharma
WEBBe Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. We are led by a world-class team of visionary scientists, drug developers and business leaders. Contact us today.
Brad Hartman - Be Biopharma
WEBBrad Hartman is a purpose-driven biotech executive and entrepreneur who is deeply committed to unlocking the potential in individuals, teams and the company to radically improve patients' lives.
Be Bio and Resilience Announce Strategic Collaboration ... - Be …
WEBMay 19, 2022 · CAMBRIDGE, Mass. & SAN DIEGO May 19, 2022 – Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline.
Rick Morgan, Ph.D. - Be Biopharma
WEBRick Morgan, Ph.D. Chief Scientific Officer. The bulk of Dr. Morgan’s career was at the National Institutes of Health (NIH) where he led a series of laboratories in the field of cell and gene therapy.
Be Bio Announces New Preclinical Data Demonstrating its Novel ...
WEBDec 10, 2023 · Engineered BCMs secreted up to 60 ng/1e6 cells/hour of FIX protein, approaching 40% of IgG secretion rate as measured by ELISA. Vitamin K-dependent activated partial thromboplastin time (aPTT), using the one stage clotting assay, demonstrated biological activity of BCM-produced FIX.